

**NOTICE OF THIRTY SECOND ANNUAL GENERAL MEETING**

SHORTER NOTICE IS HEREBY GIVEN THAT THE THIRTY SECOND ANNUAL GENERAL MEETING OF HEALTHIUM MEDTECH LIMITED IS TO BE HELD ON WEDNESDAY, 26<sup>th</sup> JUNE 2024 AT 9:30 A.M. THROUGH VIDEO CONFERENCING HOSTED FROM 8<sup>th</sup> FLOOR, INCUBEX WORKSPACES, BRIGADE TRIUMPH, DASARAHALLI MAIN ROAD, SECTOR-B, HEBBAL, BANGALORE, KARNATAKA-560092

---

**ORDINARY BUSINESS:**

1. TO RECEIVE, CONSIDER AND ADOPT THE FINANCIAL STATEMENTS (AUDITED STANDALONE & CONSOLIDATED FINANCIAL STATEMENTS) FOR THE FINANCIAL YEAR ENDED ON 31<sup>st</sup> MARCH 2024 TOGETHER WITH THE AUDITOR'S REPORT AND BOARD'S REPORT THEREON

*To consider and, if thought fit, to pass following resolution as an Ordinary Resolution:*

“RESOLVED THAT the Audited Financial Statements of the Company which includes Balance Sheet (Standalone and Consolidated) as on 31<sup>st</sup> March 2024, the Statement of Profit & Loss and Cash Flow Statement for the Financial Year ended on 31<sup>st</sup> March 2024 along with the Schedules and Notes appended thereto, Board's Report and the Auditor's Report thereon, be and are hereby received, considered and adopted.”

2. TO APPOINT S.R. BATLIBOI AND ASSOCIATES LLP AS STATUTORY AUDITORS OF THE COMPANY

*To consider and, if thought fit, to pass following resolution as an Ordinary Resolution:*

“RESOLVED THAT pursuant to provisions Section 139 and 142 read with Rule 3 of the Companies (Audit and Auditors) Rules, 2014 of the Companies Act, 2014, and other applicable provisions of the Companies Act, 2013 read with Rules made thereunder (including any statutory modification (s) or re-enactment thereof for the time being in force) the consent of the members be and is hereby accorded to appoint S.R Batliboi & Associates LLP, Chartered Accountant bearing Firm registration no. 101049W/E300004, having their Office at 12<sup>th</sup> Floor “UB City” Canberra Block No. 24, Vittal Mallya Road, Bengaluru 560001, as Statutory Auditors of the Company for a period of five years starting from Financial 2024-25 and they shall hold the office from the conclusion of this Annual General Meeting (AGM) until the conclusion of 37<sup>th</sup> Annual General Meeting (AGM) for the Financial Year 2028-29 on such remuneration as may be mutually agreed upon by the management and the auditors plus reimbursement of service tax, travelling, technology fees and out- of pocket expenses;

**RESOLVED FURTHER THAT** any of the Directors of the Company be and are severally authorized to sign the necessary e-Form with the jurisdictional Registrar of Companies, and do all such acts, deeds and things necessary and incidental in this regard.”

**3. TO DECLARE THE FINAL DIVIDEND FOR THE FINANCIAL YEAR 2023-24**

*To consider and, if thought fit, to pass following resolution as an Ordinary Resolution:*

“**RESOLVED THAT** pursuant to Section 123 and other relevant provisions of the Companies Act, 2013, read with the Companies (Declaration and Payment of Dividend) Rules, 2014, and based on the recommendation of the Board of Directors, the shareholders hereby approve the payment of a Final Dividend of INR 5.16/- per equity share of face value INR 1/- each for the financial year ended March 31, 2024, amounting to INR 50,67,08,832/- (total amount of dividend) on the equity share capital of the Company;

**RESOLVED FURTHER THAT** said dividend payment shall be made to the members whose names appear in the Register of Members as of the date of this Annual General Meeting, subject to the applicable provisions of the Foreign Exchange Management Act, 1999, and the Income Tax Act, 1961, including rules and regulations framed thereunder.

**RESOLVED FURTHER THAT** the directors of the Company be and is hereby severally authorized to do all such acts, deeds, matters and things as may be necessary, proper or expedient to give effect to this resolution.”

**SPECIAL BUSINESS:**

**4. TO RATIFY THE REMUNERATION OF THE COST AUDITOR OF THE COMPANY PAYABLE FOR THE FINANCIAL YEAR 2024-25**

*To consider and, if thought fit, to pass following resolution as Special Resolution:*

“**RESOLVED THAT** pursuant to the provisions of Section 148 of the Companies Act, 2013 read with Companies (Cost Audit and Auditors) Rules, 2014, Companies (Cost Records and Audit) Rules, 2014 or any other applicable provisions of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), consent of the members of the Company be and are hereby accorded for ratification of the remuneration of M/s. K.S. Kamalakara & Co. (FRN: 000296), Cost Accountant to INR 1,10,000/- per annum (Rupees One Lakhs Ten Thousand only) and applicable taxes thereon as per the laws in force at the time of invoicing and re-imburement of out of pocket expenses towards travelling, conveyance, lodging, boarding, etc. for the cost audit to be conducted for the Financial Year 2024-2025;

**RESOLVED FURTHER THAT** any of the Directors and /or Group CFO and/or the Company Secretary & Compliance officer of the Company be and are hereby severally authorized to file necessary to do all such acts, deeds and things as may be necessary to give effect to the above resolutions.”

**5. TO PROVIDE THE OMNIBUS APPROVAL TO THE RELATED PARTY TRANSACTION FOR THE FINANCIAL YEAR 2024-25**

***To consider and, if thought fit, to pass the following resolution as an Special Resolution:***

“**RESOLVED THAT** pursuant to the provisions of Section 188 and other applicable provisions, if any, of the Companies Act, 2013 read with the rules made there under (including any statutory modification(s) or re-enactment thereof for the time being in force), the consent of the members be and is hereby accorded to provide the omnibus approval to enter into related party transaction at Arm’s Length basis, for the Financial Year 2024-25, on such terms and conditions of which were placed before the members and for the maximum amounts per annum, as mentioned herein below:

SL NO	NATURE OF TRANSACTION	NAME OF THE RELATED PARTY	NAME OF THE DIRECTOR/KMP WHO IS RELATED AND NATURE OF THEIR RELATIONSHIP	MAXIMUM AMOUNTS (INR) IN MILLION
1	Purchase of goods and services	Quality Needles Private Limited	Subsidiary Company	250 million
2	Purchase of goods and services	CareNow Medical Private Limited	Subsidiary Company	100 million
3	Sales of goods and services	Healthium Medtech (UK) Limited	Subsidiary Company	100 million
4	Purchase of goods and services	CareNow Lifesciences Private Limited	Common Director- Anish Vanraj Bafna	50 Million
5	Cross charge of expense	Quality Needles Private Limited and CareNow Medical Private Limited	Subsidiary Company	20 Million

6	Intercorporate Loan Interest (Transferred as part of BTA from Carenow Medical Private Limited)	CareNow Lifesciences Private Limited	Common Director- Anish Vanraj Bafna	30 Million
---	--	--------------------------------------	-------------------------------------	------------

**RESOLVED FURTHER THAT** the Company is required to maintain the register in Form MBP-4 under Section 184 and 188 with respect to particulars of all contracts or arrangements and shall be placed before the board for authentication and board members hereby authorize Managing Director and/or Group CFO and/or Company Secretary & Compliance officer of the Company to authenticate the register as maintained under Form MBP-4 for and on behalf of the board;

**RESOLVED FURTHER THAT** the Board of Directors of the Company and/or Group CFO and/or Company Secretary and Compliance officer, be and are hereby severally authorised to do or cause to be done all such acts, matters, deeds and things and to settle any queries, difficulties, doubts that may arise with regard to any transaction with the related party and execute such agreements, documents and writings and to make such filings, as may be necessary or desirable for the purpose of giving effect to this resolution, in the best interest of the Company.”

**6. REGULARIZATION OF ADDITIONAL DIRECTOR, MR. MARCO BONAITI (DIN:10312765) AS NON-EXECUTIVE DIRECTOR OF THE COMPANY**

**To consider and, if thought fit, to pass with or without modifications, the following resolution as Special Resolution:**

“**RESOLVED THAT** pursuant to the provisions of Sections 161 and other applicable provisions, if any, of the Companies Act, 2013 read with Article of Association of the Company Mr. Marco Bonaiti (DIN:10312765), who was appointed as an Additional Non-Executive Director and Nominee of Quinag Acquisitions FDI Ltd by the Board of Directors of the Company with effect from 12<sup>th</sup> September, 2023 and who holds office till the conclusion of this Annual General Meeting, be and is hereby appointed as Non-Executive Director of the Company.”

**7. RE-APPOINTMENT OF MR. MOHAMMED AZEEZ (DIN: 03527725), AS A WHOLE-TIME DIRECTOR OF THE COMPANY, WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT.**

**To consider and if thought fit, to pass with or without modification(s), the following resolution as Special Resolution:**

“**RESOLVED THAT** pursuant to the provisions of Sections 196, 197 and other applicable provisions of the Companies Act, 2013, rules, circulars, orders and notifications issued thereunder (including any statutory modification(s) or re-enactment thereof for the time

being in force), read with Schedule V of the Companies Act, 2013, approval of the members of the Company be and is hereby accorded to the re-appointment of Mr. Mohammed Azeez (DIN 00022096) as a Whole-time Director of the Company , who retires by rotation to be reappointed in terms and conditions as included in his appointment letter and in terms of resolution approving is appointment passed on 4th March 2022 and shareholders resolution dated 31st May 2024 for approving his remuneration;

**RESOLVED FURTHER THAT** the Board be and is hereby authorised to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.”

**8. RATIFICATION OF RELATED PARTY TRANSACTIONS OF THE FINANCIAL YEAR 2023-24**

**To consider and if thought fit, to pass with or without modification(s), the following resolution as Special Resolution:**

**“RESOLVED THAT** pursuant to the provision of section 188 of the Companies Act, 2013 and the relevant rules made thereunder the related party transaction as mentioned in Notes to the Financial Statement carried during the Financial Year 2023-24 on the recommendation of audit committee be and is hereby ratified and taken on record;

Sl No.	Name(s) of the related party & nature of relationship	Nature of contracts/arrangement /transaction	Duration of the contract/arrangement /transaction	Salient terms of the contracts or arrangements or transaction including the value (in Mn), if any	Date of approval by the Board	Amount paid as advances, if any
1	Quality Needles Private Limited  (Subsidiary Company)	Other services provided	During the year	4.69	250 Mn approved on 23 <sup>rd</sup> June 2023	NIL
		Corporate Guarantee Commission	During the year	1	23 <sup>rd</sup> June 2023	NIL

		Purchase of goods	During the year	210.76	23 <sup>rd</sup> June 2023	NIL
		Purchase of property, plant, equipments	During the year	1.91	23 <sup>rd</sup> June 2023	NIL
		Dividend Income	During the year	1050.25		
2	Care Now Medical Private Limited	Impairment in the value of investment	During the year	776.84		NIL
		Purchase of goods	During the year	113.54	180 Mn was approv ed on 23 <sup>rd</sup> June 2023	NIL
		Other services- Rent, GMC, GPA and GTL	During the year	1.37	12 <sup>th</sup> Septe mber 2023	NIL
		Sale of goods	During the year	10.83	23 <sup>rd</sup> June 2023	NIL
		Corporate Guarantee Commission	During the year	1.20	23 <sup>rd</sup> June 2023	
		Interest Income	During the year	0.09	23 <sup>rd</sup> June 2023	NIL
		Loan Given	During the year	50	15 <sup>th</sup> Februa ry 2024	


		Loan Transferred through Business Transfer Agreement	During the year	50.09		
		Employee share based payments	During the year	23.49	23 <sup>rd</sup> June 2023	
		Rent expense	During the year	0.08	23 <sup>rd</sup> June 2023	
3	Sironix Medical Technologies B.V.	Dividend Income	During the year	172.81		NIL
		Buyback of shares	During the year	397.40		NIL
4	Sironium Medical Technologies Limited	Buyback of shares	During the year	0.43		
5	Healthium Medtech UK Limited	Sale of goods	During the year	35.37	50 Mn was approved on 23 <sup>rd</sup> June 2023	
6	Carenow Lifesciences Private Limited	Loan transferred through Business Transfer Agreement	During the year	50.09		
		Interest Income	During the year	0.29		
		Other services provided	During the year	0.21		

**RESOLVED FURTHER THAT** the register maintained under Section 184 and 188 with respect to particulars of all contracts or arrangements in Form MBP-4 has been placed before the board for authentication and board members hereby authorize Managing Director and/or Group CFO and/or Company Secretary & Compliance officer of the Company to authenticate the register as maintained under Form MBP-4 for and on behalf of the board;

**RESOLVED FURTHER THAT** any of the directors and/or Group CFO and/ or the Company Secretary and Compliance officer of the Company is authorized to certify the true copy of the aforesaid resolutions.”

By Order of the Board of Directors  
For **Healthium Medtech Limited**

*Pallavi*



**Pallavi Karkera**

**Designation: Company Secretary**

**Membership No.: F10224**

**Address: No. 6003, Prestige Monte Carlo,  
Yelahanka Newtown, Bangalore - 560064**

**Date: 25<sup>th</sup> June 2024**

**Place: Bangalore**



## NOTES

1. The Explanatory Statement under Section 102 of the Companies Act, 2013, in respect of the business matter is annexed herewith and forms part of the notice.
2. The documents referred to in the Resolutions can be inspected at the Registered Office of the Company in 472/D, 4<sup>th</sup> Phase, 13<sup>th</sup> Cross, Peenya Industrial Area, Bangalore - 560058 during 11 am to 5 pm on all working days of the Company.
3. Pursuant to Section 20(2) of the Companies Act, 2013 read with Rule 35 of the Companies (Incorporation) Rules, 2014, as amended, companies are permitted to send official documents to their shareholders electronically.
4. In continuation to this Ministry's General Circular No. 10/ 2022 dated 28.12.2022 read with Circular No. 14/ 2020 dated 8.04.2020 and General Circular No. 3/2022 dated 05.05.2020 and other circulars issued from time to time (collectively referred to as 'MCA Circulars') after due examination, it has been decided to allow companies to conduct their AGMs through Video Conference (VC) or Other Audio Visual Means (OAVM) or transact item through postal ballot in accordance with the framework provided in the aforesaid circulars up to 25.09.2023. All other requirements provided in the said Circulars shall remain unchanged.  
In compliance with the provisions of the Companies Act, 2013 ("Companies Act"), MCA Circulars, the AGM of the Company is being held through video conferencing ("VC") facility. Hence, members must attend and participate in the ensuing AGM through VC.
5. This meeting is being called at a shorter notice than the statutory required minimum of 21 clear days. Pursuant to the provisions of Section 101 of the Companies Act, 2013, a general meeting other than AGM may be called after giving a shorter notice if consent is given in writing or by electronic mode by not less than ninety-five per cent. of the members entitled to vote thereat. The members have accordingly given their consents to hold the meeting at a shorter notice.
6. The members can join the AGM through VC mode 15 minutes before and after the scheduled time of the commencement of the meeting by following the procedure mentioned in the Notice.
7. The attendance of the members attending the AGM through VC will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act.
8. Pursuant to the provisions of the Companies Act, a member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars through VC, physical attendance of members has been dispensed with. Accordingly, the facility for appointment of proxies by the members will not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice.
9. In compliance with the aforesaid MCA Circulars, Notice of the AGM as well as the weblink for joining the meeting is being sent only through electronic mode to those members whose email addresses are registered with the Company.

10. Those shareholders whose email IDs are not registered, are requested to register their email ID with the Company, by providing their Name, Address, email ID, PAN, Folio Number and Number of shares held by them by sending an email to [pallavi.k@healthiummedtech.com](mailto:pallavi.k@healthiummedtech.com).
11. All documents referred to in the Notice will be open for inspection through electronic mode during the AGM.
12. Since the AGM will be held through VC, the Route Map is not annexed in this Notice. The scheduled venue of the meeting as set forth in the notice convening the meeting, shall be deemed to be the place of the said meeting and all recordings of the proceedings at the meeting shall be deemed to be made at such place.
13. The Members will be allowed to pose questions during the course of the Meeting. The queries can also be given in advance at to [pallavi.k@healthiummedtech.com](mailto:pallavi.k@healthiummedtech.com).

**Instructions for Members for attending the AGM through VC are as under:**

- a) An invitation to join the AGM will be sent to the members on their latest registered email IDs by [pallavi.k@healthiummedtech.com](mailto:pallavi.k@healthiummedtech.com)
- b) Members may attend the AGM, by following the invitation link sent to their registered email ID. Members will be able to locate Meeting ID/ Password/ and *Join Meeting* tab. By clicking on *Join Meeting* they will be redirected to Meeting Room via browser or by running Temporary Application. To join the Meeting, follow the step and provide the required details (mentioned above – Meeting ID/Password/Email Address) and Join the Meeting. Members are encouraged to join the Meeting through laptops for better experience.
- c) In case of Android / iPhone connection, Participants will be required to download and Install the appropriate application as given in the mail to them. Application may be downloaded from Google Play Store / App Store.
- d) Further, members will be required to allow camera and use Internet audio settings as and when asked while setting up the meeting on mobile application.
- e) Please note that participants connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio / Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

The helpline number for joining the meeting through electronic mode will be provided in the meeting invitation which will be sent to the eligible applicants.

## ANNEXURE - I

### **EXPLANATORY STATEMENT AS PER THE PROVISIONS OF SECTION 102(1) OF THE COMPANIES ACT, 2013**

#### **ITEM NO. 4**

#### **RATIFY THE REMUNERATION OF THE COST AUDITOR OF THE COMPANY PAYABLE FOR THE FINANCIAL YEAR 2024-25**

As per Section 148 of The Companies Act, 2013 read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014 the Board is required to appoint a cost auditor to audit the cost records of the applicable products of the Company. As per the Rules, remuneration payable to the cost auditor is required to be approved by the members of the Company in their subsequent general meeting.

In view of the above, it is to be hereby informed that, the Board of Directors of the Company at its meeting held on 25<sup>th</sup> June 2024 has considered and approved the appointment of M/s. K.S. KAMALAKARA & CO. (FRN: 000296), Cost Accountants, as the cost auditor of the Company for the financial year 2024-25 and at such remuneration of INR 1,10,000/-per annum (Indian Rupees One Lakhs Ten Thousand only) and applicable taxes thereon as per the laws in force at the time of invoicing and re-imburement of out of pocket expenses towards travelling, conveyance, lodging, boarding, etc., subject to ratification by the members.

None of the directors and/or their relatives is in any way concerned and/or interested, either financially or otherwise, in passing the proposed resolution, save and except to the extent of their respective interest as members of the Company.

The board of directors of the Company recommends the resolutions set out at Item No. 4 of the accompanying Notice for your approval as special resolution.

#### **ITEM NO. 5**

#### **TO PROVIDE THE OMNIBUS APPROVAL OF RELATED PARTY TRANSACTION FOR THE FINANCIAL YEAR 2024-25**

Pursuant to provisions of Section 188 of the Companies Act, 2013 ("the Act"), read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014 the Company is required to obtain consent of the Board and prior approval of the members by resolution for certain Related Party Transactions which exceed such sum as is specified in the rules. The aforesaid provisions are not

applicable in respect to transactions entered into by the Company in the ordinary course of business and on an arm's length basis.

However, as a measure of transparency, the company every year is obtaining approval of shareholders for the related party transactions to ensure that all the related party transactions entered by the company at any given point of time are according to the prior approval of the shareholders.

The board has provided its omnibus approval to the related party transactions of the Financial Year 2024-25 in the board meeting held on 25<sup>th</sup> June 2024.

SL	NATURE OF TRANSACTION	NAME OF THE RELATED PARTY	NAME OF THE DIRECTOR/KMP WHO IS RELATED AND NATURE OF THEIR RELATIONSHIP	MAXIMUM AMOUNTS (INR) IN MILLION
1	Purchase of goods and services	Quality Needles Private Limited	Subsidiary Company	250 Million
2	Purchase of goods and services	Carenow Medical Private Limited	Subsidiary Company	100 Million
3	Sales of goods and services	Healthium Medtech (UK) Limited	Step-down Subsidiary Company	100 Million
4	Purchase of goods and services	Carenow Lifesciences Private Limited	Common directors- Anish Vanraj Bafna	50 Million
5	Cross charge of expense	Quality Needles Private Limited and Carenow Medical Private Limited	Subsidiary Company	20 Million
6	Intercorporate Loan Interest (Transferred as part of BTA from Carenow Medical)	Carenow Lifesciences Private Limited	Common directors- Anish Vanraj Bafna	30 Million

None of the directors and/or their relatives is in any way concerned and/or interested, either financially or otherwise, in passing the proposed resolution, save and except to the extent of their respective interest as members of the Company.

Hence, it is recommended the resolution no. 5 of this notice as Special Resolution for the approval of shareholders.

#### **ITEM NO 6**

#### **REGULARIZATION OF ADDITIONAL DIRECTOR, MR. MARCO BONAITI (DIN:10312765) AS NON-EXECUTIVE DIRECTOR OF THE COMPANY**

Mr. Marco Bonaiti was appointed as an additional non-executive director and nominee of Quinag Acquisition FDI Ltd with effect from September 12, 2023. His term as an additional director will conclude at the Annual General Meeting. The Nomination and Remuneration Committee and the Board of Directors approved and recommended his appointment as a non-executive director, not liable to retire by rotation, in their meeting on June 25, 2024.

Except Mr. Marco Bonaiti, none of the directors or their relatives have any financial or other interests in passing the proposed resolution, except to the extent of their respective interests as members of the Company.

Hence, it is recommended the resolution no. 6 of this notice as Special Resolution for the approval of shareholders.

#### **ITEM NO 7.**

#### **RE-APPOINTMENT OF MR. MOHAMMED AZEEZ (DIN: 03527725), AS A WHOLE-TIME DIRECTOR OF THE COMPANY, WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT**

Mr. Mohammed Azeez was appointed as a Whole-time Director of the Company in the shareholders' meeting held on 4<sup>th</sup> March 2022, to hold office for five years until 3<sup>rd</sup> March 2027.. As per the provisions of Section 152(6) of the Companies Act, he is retiring by rotation and offers himself for reappointment as a Whole-time Director of the Company.

His reappointment and remuneration will be governed by his appointment letter and the resolutions passed by the shareholders in their meetings held on 4<sup>th</sup> March 2022 and 31<sup>st</sup> May 2024.

Except Mr. Mohammed Azeez, none of the directors and/or their relatives is in any way concerned and/or interested, either financially or otherwise, in passing the proposed resolution, save and except to the extent of their respective interest as members of the Company.

Hence, it is recommended the resolution no. 7 of this notice as Special Resolution for the approval of shareholders.

**ITEM NO 8.**

**RATIFICATION OF RELATED PARTY TRANSACTION OF THE FINANCIAL YEAR 2023-24**

Pursuant to provisions of Section 188 of the Companies Act, 2013 ("the Act"), the Company is required to obtain consent of the Board and ratification of the members by resolution for certain Related Party Transactions which were entered into by the company in the previous financial year i.e. 2023-24. The aforesaid provisions are not applicable in respect to transactions entered into by the Company in the ordinary course of business and on an arm's length basis.

SI No.	Name(s) of the related party & nature of relationship	Nature of contracts/arrangement/transaction	Duration of the contract/arrangement/transaction	Salient terms of the contracts or arrangements or transaction including the value (in Mn), if any	Date of approval by the Board	Amount paid as advances, if any
1	Quality Needles Private Limited  (Subsidiary Company)	Other services provided	During the year	4.69	250 Mn approved on 23 <sup>rd</sup> June 2023	NIL
		Corporate Guarantee Commission	During the year	1	23 <sup>rd</sup> June 2023	NIL
		Purchase of goods	During the year	210.76	23 <sup>rd</sup> June 2023	NIL
		Purchase of property, plant, equipments	During the year	1.91	23 <sup>rd</sup> June	NIL

3	Sironix Medical Technologies B.V.	Dividend Income	During the year	172.81		NIL
		Buyback of shares	During the year	397.40		NIL
4	Sironium Medical Technologies Limited	Buyback of shares	During the year	0.43		
5	Healthium Medtech UK Limited	Sale of goods	During the year	35.37	50 Mn was approved on 23 <sup>rd</sup> June 2023	
6	Carenow Lifesciences Private Limited	Loan transferred through Business Transfer Agreement	During the year	50.09		
		Interest Income	During the year	0.29		
		Other services provided	During the year	0.21		


Except Mr. Mohammed Azeez and Mr. Anish Vanraj Bafna, none of the directors and/or their relatives is in any way concerned and/or interested, either financially or otherwise, in passing the proposed resolution, save and except to the extent of their respective interest as directors of the Company.

Hence, it is recommended the resolution no. 8 of this notice as Special Resolution for the approval of shareholders.

By Order of the Board of Directors

For **Healthium Medtech Limited**

*Pallavi*



**Pallavi Karkera**

**Designation: Company Secretary**

**Membership No.: 10224**

**Address: No. 6003, Prestige Monte Carlo,  
Yelahanka Newtown, Bangalore - 560064**

**Date: 25<sup>th</sup> June 2024**

**Place: Bangalore**

					2023	
		Dividend Income	During the year	1050.25		
2	Care Now Medical Private Limited	Impairment in the value of investment	During the year	776.84		NIL
		Purchase of goods	During the year	113.54	180 Mn was approved on 23 <sup>rd</sup> June 2023	NIL
		Other services- Rent, GMC, GPA and GTL	During the year	1.37	12 <sup>th</sup> September 2023	NIL
		Sale of goods	During the year	10.83	23 <sup>rd</sup> June 2023	NIL
		Corporate Guarantee Commission	During the year	1.20	23 <sup>rd</sup> June 2023	
		Interest Income	During the year	0.09	23 <sup>rd</sup> June 2023	NIL
		Loan Given	During the year	50	15 <sup>th</sup> February 2024	
		Loan Transferred through Business Transfer Agreement	During the year	50.09		
		Employee share based payments	During the year	23.49	23 <sup>rd</sup> June 2023	
		Rent expense	During the year	0.08	23 <sup>rd</sup> June 2023	